Priming knowledge in liver
cancer across disciplines
-
ClarIDHy: A global, phase 3, randomized, double-blind study of ivosidenib (IVO) vs placebo in patients with advanced cholangiocarcinoma (CC) with an isocitrate dehydrogenase 1 (IDH1) mutation
Annals of Oncology, September 2019 -
CheckMate 459: A Randomized, Multi-Center Phase 3 Study of Nivolumab (NIVO) vs Sorafenib (SOR) as First-Line (1L) Treatment in Patients (pts) With Advanced Hepatocellular Carcinoma (aHCC)
Annals of Oncology, September 2019 -
Association of liver-directed local therapy with overall survival in adults with metastatic intrahepatic cholangiocarcinoma
JAMA Network Open, September 2019 -
Assessment of treatment with sorafenib plus doxorubicin vs sorafenib alone in patients with advanced hepatocellular carcinoma. Phase 3 CALGB 80802 randomized clinical trial
JAMA Oncology, 5 September 2019 -
Proof of concept study of efficacy of FGFR4 inhibitors in hepatocellular carcinomas
Cancer Discovery, October 2019
The International Liver Cancer Association (ILCA) is the only international organisation devoted exclusively to liver cancer research for experts from all related disciplines.
Our mission is to lead a global Community of physicians, scientists and allied professionals through education and research with the goal to better prevent and treat liver cancer.
We will do so by promoting novel pathogenic, diagnostic and therapeutic interventions for liver cancer by taking a transversal approach to research and bringing together scientists, physicians and allied professionals from all interrelated fields.